Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C
Status:
Completed
Trial end date:
2017-03-30
Target enrollment:
Participant gender:
Summary
1. Study objective: To assess the efficacy and safety of collagen matrix implant (Ologen®;
OLO) in phacotrabeculectomy and to compare with mitomycin C (MMC) augmented
phacotrabeculectomy.
2. Study Design: The study is designed as a prospective randomized trial. Patient who meet
the inclusion/exclusion criteria and sign the informed consent form will be included for
this study.
3. Follow-Up: This investigation is including 7 post-operative visits and follow-up within
12 months from the date of surgery. Patients should be seen at postoperative days 1, 7,
30, 90, 180, 270 and 360.